Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 204

1.

State of the art: Reproduction and pregnancy in rheumatic diseases.

Østensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, Costedoat-Chalumeau N, Cutolo M, Dolhain R, Fenstad MH, Förger F, Wahren-Herlenius M, Ruiz-Irastorza G, Koksvik H, Nelson-Piercy C, Shoenfeld Y, Tincani A, Villiger PM, Wallenius M, von Wolff M.

Autoimmun Rev. 2015 May;14(5):376-386. doi: 10.1016/j.autrev.2014.12.011. Epub 2014 Dec 30. Review.

PMID:
25555818
2.

[Sex hormones, immune disorders, and inflammatory rheumatic diseases].

Kaliterna DM, Perković D, Radić M, Krstulović DM, Borić K, Marinović I.

Reumatizam. 2014;61(1):17-22. Croatian.

PMID:
25509832
3.

Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis.

Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg ÁM.

PLoS One. 2014 Aug 19;9(8):e104303. doi: 10.1371/journal.pone.0104303. eCollection 2014.

4.

How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.

Thanou A, Chakravarty E, James JA, Merrill JT.

Rheumatology (Oxford). 2014 Dec;53(12):2175-81. doi: 10.1093/rheumatology/keu153. Epub 2014 Apr 11.

PMID:
24729400
5.

Impact of ovarian function on cardiovascular health in women: focus on hypertension.

Maric-Bilkan C, Gilbert EL, Ryan MJ.

Int J Womens Health. 2014 Jan 24;6:131-9. doi: 10.2147/IJWH.S38084. eCollection 2014. Review.

6.

17β-Estradiol protects against the progression of hypertension during adulthood in a mouse model of systemic lupus erythematosus.

Gilbert EL, Mathis KW, Ryan MJ.

Hypertension. 2014 Mar;63(3):616-23. doi: 10.1161/HYPERTENSIONAHA.113.02385. Epub 2013 Dec 23.

7.

Estrogen: good, bad, or both?

Rafikova O, Sullivan JC.

Hypertension. 2014 Mar;63(3):449-50. doi: 10.1161/HYPERTENSIONAHA.113.02500. Epub 2013 Dec 23. No abstract available.

8.

Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy.

Ma W, Zhan Z, Liang X, Chen J, Huang X, Liao C.

J Womens Health (Larchmt). 2013 Dec;22(12):1023-7. doi: 10.1089/jwh.2013.4255.

9.

Putative effects of potentially anti-angiogenic drugs in rheumatic diseases.

Maruotti N, Cantatore FP, Ribatti D.

Eur J Clin Pharmacol. 2014 Feb;70(2):135-40. doi: 10.1007/s00228-013-1605-6. Epub 2013 Nov 7. Review.

PMID:
24196651
10.
11.

Development of systemic lupus erythematosus in a male-to-female transsexual: the role of sex hormones revisited.

Chan KL, Mok CC.

Lupus. 2013 Nov;22(13):1399-402. doi: 10.1177/0961203313500550. Epub 2013 Jul 29.

PMID:
23897544
12.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

13.

17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice.

Shelton KA, Cline JM, Cann JA.

Atherosclerosis. 2013 Apr;227(2):228-35. doi: 10.1016/j.atherosclerosis.2012.12.031. Epub 2013 Jan 18.

14.

Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy.

Aikawa NE, Sallum AM, Pereira RM, Suzuki L, Viana VS, Bonfá E, Silva CA.

Clin Exp Rheumatol. 2012 May-Jun;30(3):445-9. Epub 2012 Jun 26.

PMID:
22703605
15.

Hormonal parameters and sex hormone receptor gene polymorphisms in men with autoimmune diseases.

Doukas C, Saltiki K, Mantzou A, Cimponeriu A, Terzidis K, Sarika L, Mavrikakis M, Sfikakis P, Alevizaki M.

Rheumatol Int. 2013 Mar;33(3):575-82. doi: 10.1007/s00296-012-2386-4. Epub 2012 Mar 31.

PMID:
22466402
16.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.

Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.

17.

Hormone replacement and contraceptive therapy in autoimmune diseases.

Lateef A, Petri M.

J Autoimmun. 2012 May;38(2-3):J170-6. doi: 10.1016/j.jaut.2011.11.002. Epub 2012 Jan 18. Review.

PMID:
22261500
18.

Familial SLE: sustained drug-free remission in a mother successfully treated for anal cancer, but development of SLE in a 16-year old daughter.

Catania G, Rossi E, Marmont A.

Lupus. 2012 May;21(6):672-4. doi: 10.1177/0961203311433138. Epub 2012 Jan 11.

PMID:
22236910
19.

[Connective tissue diseases during pregnancy - therapeutic aspect. Part 1: SLE, antiphosholipid syndrome].

Putała-Pośpiech M, Robak E.

Przegl Lek. 2012;69(11):1220-5. Review. Polish.

PMID:
23646451
20.

Sex differences in spontaneous versus induced animal models of autoimmunity.

Lee TP, Chiang BL.

Autoimmun Rev. 2012 May;11(6-7):A422-9. doi: 10.1016/j.autrev.2011.11.020. Epub 2011 Dec 4. Review.

PMID:
22172712
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk